HLA-G expression in acute lymphoblastic leukemia: A significant prognostic tumor biomarker

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Alkhouly, Noura ^a   Shehata, Iman ^a   Ahmed, Manal Basyouni ^a   Shehata, Hanan ^a   Hassan, Sara ^a   Ibrahim, Tamer ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Acute lymphoblastic leukemia; HLA G; IL 10; INF ; NK cells

Indexed keywords

GAMMA INTERFERON; HLA G ANTIGEN; INTERLEUKIN 10; LACTATE DEHYDROGENASE; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; LEUKOCYTE COUNT; NATURAL KILLER CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HLA-G ANTIGENS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84872271298     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0460-8     Document Type: Article

References (46)

1. Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, Kantarjian HM. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer. 2010;116(5):1165-76.
2. Akinloye O, Adegbenro M, Olaniyi J, Rahamon S, Anifowose A, Awosika E, Arinola G. Plasma interferon-gamma and IL-4, immunoglobulin classes and nitric oxide in nigerians with acute leukaemia. ©Sierra Leone J Biomed Res. 2011;3(3):138-43.
3. Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunother. 2001;24:392-407.
4. Carosella ED, Moreau P, Lemaoult J, Rouas-Freiss N. HLA-G: from biology to clinical benefits. Trends Immunol. 2008;29(3):125-32.
5. LeMaoult J, Zafaranloo K, Le Danff C, Carosella ED. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J. 2005;19(6):662-4.
6. Kovats S, Main EK, Librach C, et al. A class I antigen, HLA-G, expressed in human trophoblasts. Science. 1990;248:220-3.
7. Blaschitz A, Lenfant F, Mallet V, et al. Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G. Eur J Immunol. 1997;27:3380-8.
8. Yang Y, Chu W, Geraghty DE, Hunt JS. Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-gamma. J Immunol. 1996;156:4224-31.
9. Crisa L, McMaster MT, Ishii JK, et al. Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. J Exp Med. 1997;186:289-98.
10. Le Rond S, Le Maoult J, Créput C, Menier C, Deschamps M, Le Friec G, Amiot L, Durrbach A, Dausset J, Carosella ED. Rouas-FreissN. Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions: in vivo implications in transplanted patients. Eur J Immunol. 2004;34(3):649-60.
11. Cabestre A, Moreau P, Riteau B, et al. HLA-G expression in human melanoma cells: protection from NK cytolysis. J Reprod Immunol. 1999;43:183-93.
12. Urosevic M, Willers J, Mueller B, Kempf W, Burg G, Dummer R. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood. 2002;99:609-17.
13. Urosevic M, Kurrer MO, Kamarashev J, et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade, human histology, leukocyte antigen class I loss and interleukin-10 production. Am J Pathol. 2001;159:817-24.
14. Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol. 2007;20:375-83.
15. Colombo MP, Trinchieri G. Cytokines and cancer. Cytokine Growth Factor Rev. 2002;13:93-4.
16. Wu S, Gessner R, Taube T, von Stackelberg A, Henze G, Seeger K. Expression of interleukin-10 splicing variants is a positive prognostic feature in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:3038-42.
17. Cloppenborg T, Stanulla M, Zimmermann M, Schrappe M, Welte K, Klein C. Immunosurveillance of childhood ALL: polymorphic interferon-gamma Alleles are associated with age at diagnosis and clinical risk groups. Leukaemia. 2005;19:44-8.
18. Onno M, Le Friec G, Pangault C, Amiot L, Guilloux V, Drenou B, et al. Modulation of HLA-G antigens expression in myelomonocylic cells. Hum Immunol. 2000;61:1086-94.
19. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev. 2006;20:123-37.
20. Fregni G, Perie A, Avril M, Caignard A. NK cells sense tumors, course of disease and treatments consequences for NK-based therapies. Onco Immunol. 2012;1(1):38-47.
21. Soderstrom K, Corliss B, Lanier LL, Phillips JH. CD94/NKG2 is the predominant inhibitory receptor involved in recognition of HLA-G by decidual and peripheral blood NK cells. J Immunol. 1997;159:1072-5.
22. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
23. Hoelzer D, Thiel E, Loffler H, et al. Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood. 1984;64(1):38-47.
24. Nilsson C, Aboud S, Karlen K, Hejdeman B, Urassa W, Biberfeld G. Optimal blood mononuclear cell isolation procedures for gamma interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects. Clin Vaccine Immunol. 2008;15(4):585-9.
25. Yie SM. Hu Z human leukocyte antigen-G (HLA-G) as a marker for diagnosis, prognosis and tumor immune escape in human malignancies. Histol Histopathol. 2011;26(3):409-20.
26. Nuckel H, Rebmann V, Durig J, Duhrsen U, Grosse-Wilde H. HLA-G expression is associated-with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood. 2005;105(4):1694-8.
27. Yan WH, Lin A, Chen BG, et al. Unfavorable clinical implications for HLA-G expression in acute myeloid leukemia. J Cell Mol Med. 2008;12(3):889-98.
28. Rezvany M, Kazemi A, Hajifathali A, Kaviani S, Mellstedt H. Analysis of HLA-G gene expression in B-Lymphocytes from chronic lymphocytic leukemia patients. Iran Biomed J. 2007;11(2):125-9.
29. Erikci AA, Karagoz B, Ozyurt M, Ozturk A, Kilic S, Bilgi O. HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker? Hematology. 2009;14(2):101-5.
30. Agaugue' S Carosella E, Rouas-Freiss N. Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokine balance in favor of Th2 versus Th1/Th17. Blood. 2011;117(26):7021-31.
31. Urosevic M, Dummer R. HLA-G and IL-10 expression in human cancer different stories with the same message. Semin Cancer Biol. 2003;13:337-42.
32. Drabko K, Bojarska-Junak A, Kowalczyk J. Serum concentration of IL-2, IL-4, IL-10 and TNF-α in children with acute lymphoblastic leukemia - possible role of oxidative stress. Eur J Immunol. 2008;33(3):146-9.
33. Bien E, Balcerska A, Adamkiewicz-Drozynska E, Rapala M, Krawczyk M, Stepinski J. Pre-treatment serum levels of interleukin-10, interleukin-12 and their ratio predict response to therapy and probability of event-free and overall survival in childhood soft tissue sarcomas, Hodgkin's lymphomas and acute lymphoblastic leukemias. Clin Biochem. 2009;42:1144-57.
34. Haddad JJ, Fahlman CS. Redox and oxidant mediated regulation of interleukin-10: an anti-inflammatory, anti-oxidant cytokine? Biochem Biopys Res Commun. 2002;297:163-76.
35. Choi MS, Ray R, Zhaug Z, Mukherjee AB. IFN-gamma stimulates the expression of a novel secretoglobin that regulates chemotactic cell migration and invasion. J Immunol. 2004;172(7):4245-52.
36. Fujii H, Trudeau JD, Teachey DT, Fish JD, Grupp SA, Schultz KR, Reid GS. In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides. Blood. 2007;109(5):2008-13.
37. Varela N, Munoz-Pinedo C, Ruiz-Ruiz C, Robledo G, Pedroso M, López-Rivas A. Interferon-γ sensitizes human myeloid leukemia cells to death receptor-mediated apoptosis by a pleiotropic mechanism. J Biol Chem. 2001;276(21):17779-87.
38. Kholoussi M, Bayoumi F, El-Nady H. Estimation of serum interferon-gamma level in childhood acute lymphoblastic leukemia patients. J Med Sci. 2008;8(1):68-72.
39. Tuncer AM, Hiçsönmez G, Gümrük F, Sayli T, Güler E, Cetin M, Okur H. Serum TNF-alpha. gamma-INF. G-CSF and GM-CSF levels in neutropenic children with acute leukemia treated with short-course, high-dose methylprednisolone. Leuk Res. 1996;20(3):265-9.
40. Ghosh S, Bandyopadhyay S, Mallick A, Pal S, Vlasak R, Bhattacharya DK, Mandal C. Interferon-gamma promotes survival of lymphoblasts overexpressing 9-0-acetylated sialoglycoconjugates in childhood Acute Lymphoblastic Leukemia (ALL). J Cell Biochem. 2005;95(1):206-16.
41. Sheu J, Shih L. HLA-G and immune evasion in cancer cells. Formos Med Assoc. 2010;109(4):248-57.
42. Mizuno S, Emi N, Kasai M, Ishitani A, Saito H. Aberrant expression of HLA-G antigen in interferon gamma-stimulated acute myelogenous leukaemia. Br J Haematol. 2000;111:280-2.
43. Wagner SN, Rebmann V, Willers CP, Grosse-Wilde H, Goos M. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. Lancet. 2000;356(9225):220-1.
44. Rouas-Freiss N, Goncalves RM, Menier C, Dausset J, Carosella ED. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA. 1997;94:11520-5.
45. Jarosz M, Hak L, Wieckiewicz J, Balcerska A, Myoeliwska J. NK cells in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma after cessation of intensive chemotherapy. Centr Eur J Immunol. 2009;34(2):94-9.
46. Alanko S, Salmi TT, Pelliniemi TT. Recovery of natural killer cells after chemotherapy for childhood acute lymphoblastic leukemia and solid tumors. Med Pediatr Oncol. 1995;24:373-8.